BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 22257681)

  • 1. Neoplastic "Black Ops": cancer's subversive tactics in overcoming host defenses.
    Biragyn A; Longo DL
    Semin Cancer Biol; 2012 Feb; 22(1):50-9. PubMed ID: 22257681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-host immune interactions and dendritic cell dysfunction.
    Yang L; Carbone DP
    Adv Cancer Res; 2004; 92():13-27. PubMed ID: 15530555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cancer immunotherapy. Importance of overcoming immune suppression].
    Malvicini M; Puchulo G; Matar P; Mazzolini G
    Medicina (B Aires); 2010; 70(6):565-70. PubMed ID: 21163748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].
    Benchetrit F; Gazagne A; Adotevi O; Haicheur N; Godard B; Badoual C; Fridman WH; Tartour E
    Bull Cancer; 2003; 90(8-9):677-85. PubMed ID: 14609756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet-Mediated Protection of Cancer Cells From Immune Surveillance - Possible Implications for Cancer Immunotherapy.
    Schmied L; Höglund P; Meinke S
    Front Immunol; 2021; 12():640578. PubMed ID: 33777033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tryptophan metabolites: a scent signature for cancer's immunosuppressive status?
    Zhang W
    Cancer Biol Ther; 2009 Jul; 8(14):1409-10. PubMed ID: 19502814
    [No Abstract]   [Full Text] [Related]  

  • 7. Strategies of tumor immune evasion.
    Seliger B
    BioDrugs; 2005; 19(6):347-54. PubMed ID: 16392887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utilization of chemokines to combat cancer: the double-edged sword.
    Dell'Agnola C; Biragyn A
    Expert Rev Vaccines; 2007 Apr; 6(2):267-83. PubMed ID: 17408375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The biological rationale for immunotherapy in cancer].
    Benzaquen J; Marquette CH; Glaichenhaus N; Leroy S; Hofman P; Ilié M
    Rev Mal Respir; 2018 Feb; 35(2):206-222. PubMed ID: 29428191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression.
    Ahmad M; Rees RC; Ali SA
    Cancer Immunol Immunother; 2004 Oct; 53(10):844-54. PubMed ID: 15197495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges and prospects of immunotherapy as cancer treatment.
    Rescigno M; Avogadri F; Curigliano G
    Biochim Biophys Acta; 2007 Sep; 1776(1):108-23. PubMed ID: 17720322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Janus face of dendritic cells in cancer.
    Chaput N; Conforti R; Viaud S; Spatz A; Zitvogel L
    Oncogene; 2008 Oct; 27(45):5920-31. PubMed ID: 18836473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
    Cancel JC; Crozat K; Dalod M; Mattiuz R
    Front Immunol; 2019; 10():9. PubMed ID: 30809220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It.
    Shklovskaya E; Rizos H
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunologic mechanisms of antitumor activity.
    Foss FM
    Semin Oncol; 2002 Jun; 29(3 Suppl 7):5-11. PubMed ID: 12068382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Covert operations: cancer's many subversive tactics in overcoming host defenses.
    Longo DL
    Trans Am Clin Climatol Assoc; 2013; 124():163-73. PubMed ID: 23874020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploiting regulatory T-cell populations for the immunotherapy of cancer.
    van der Vliet HJ; Koon HB; Atkins MB; Balk SP; Exley MA
    J Immunother; 2007 Sep; 30(6):591-5. PubMed ID: 17667522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell death and cancer immune tolerance.
    Lu B; Finn OJ
    Cell Death Differ; 2008 Jan; 15(1):70-9. PubMed ID: 18007660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory B cells and T cell Regulation in Cancer.
    Horii M; Matsushita T
    J Mol Biol; 2021 Jan; 433(1):166685. PubMed ID: 33096106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting regulatory T cells.
    Ménétrier-Caux C; Curiel T; Faget J; Manuel M; Caux C; Zou W
    Target Oncol; 2012 Mar; 7(1):15-28. PubMed ID: 22327882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.